TY - JOUR
T1 - Efficient purification of rhG-CSF and its PEGylated forms and evaluation for in vitro activities
AU - Tiwari, Dileep
AU - Haque, Shafiul
AU - Jawed, Arshad
AU - Mishra, Maheshwari K.
AU - Govender, Thavendran
AU - Kruger, Hendrik G.
N1 - Publisher Copyright:
© 2015 Bentham Science Publishers.
PY - 2015/8/1
Y1 - 2015/8/1
N2 - Granulocyte-colony stimulating factor (G-CSF) has commonly been used to help the patients to recover from neutropenia inflicted due to radiotherapy, organ transplants and chemotherapy. As the number of people undergoing these therapies and procedures are increasing world-wide, the need for more economical ways of G-CSF production and improvement in its efficacy has become increasingly crucial. In the present study, recombinant human G-CSF (rhG-CSF) was expressed in E. coli and its purification process was optimized by demonstrating better efficiency and higher recoveries (upto 54%) in a multi-step chromatographic purification process, which is greater than the existing reports. Additionally, the efficacy of rhG-CSF was increased by derivatizing with polyethylene glycol (PEG; upto 85% PEGylation), which increases the plasma clearance time, reduces the immunogenicity and requires less frequent administration to the patient. Overall, the present study suggests a cost-effective purification process of rhG-CSF and also proposes its efficient conjugation with PEG for enhanced efficacy as compared to the existing commercially available forms.
AB - Granulocyte-colony stimulating factor (G-CSF) has commonly been used to help the patients to recover from neutropenia inflicted due to radiotherapy, organ transplants and chemotherapy. As the number of people undergoing these therapies and procedures are increasing world-wide, the need for more economical ways of G-CSF production and improvement in its efficacy has become increasingly crucial. In the present study, recombinant human G-CSF (rhG-CSF) was expressed in E. coli and its purification process was optimized by demonstrating better efficiency and higher recoveries (upto 54%) in a multi-step chromatographic purification process, which is greater than the existing reports. Additionally, the efficacy of rhG-CSF was increased by derivatizing with polyethylene glycol (PEG; upto 85% PEGylation), which increases the plasma clearance time, reduces the immunogenicity and requires less frequent administration to the patient. Overall, the present study suggests a cost-effective purification process of rhG-CSF and also proposes its efficient conjugation with PEG for enhanced efficacy as compared to the existing commercially available forms.
KW - Chromatography
KW - Neutropenia
KW - Pegylation
KW - Purification
KW - Rhg-csf
UR - https://www.scopus.com/pages/publications/84940825986
U2 - 10.2174/0929866522666150728115146
DO - 10.2174/0929866522666150728115146
M3 - Artículo
C2 - 26216266
AN - SCOPUS:84940825986
SN - 0929-8665
VL - 22
SP - 877
EP - 884
JO - Protein and Peptide Letters
JF - Protein and Peptide Letters
IS - 10
ER -